Teva launches generic Actos

Brand Actos to improve blood sugar control in adults with type 2 diabetes has annual sales of $2.7 billion in the US.

On Friday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) launched generic versions of Actos and ACTOplus met, used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Brand Actos had annual sales of $2.7 billion in the US and ACTOplus met has $413 million in annual sales, based on IMS sales data. Both products are made by made by Japan's Takeda Pharmaceuticals Ltd. (TSE: 4502).

Teva did not obtain marketing exclusivity. Mylan Inc. (NYSE: MYL) and India's Ranbaxy Laboratories Ltd. (BSE: 500359). Watson Pharmaceuticals Inc. (NYSE: WPI) also plans to market generic Actos, and are waiting for US Food and Drug Administration (FDA) approval. The company also asked for 180 days marketing exclusivity.

Published by Globes [online], Israel business news - - on August 19, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017